Loading
A phase 1/2 trial of MHB036C in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, active and no longer recruiting.
A Study of MHB036C for Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT06373406 by Minghui Pharmaceutical (Hangzhou) Ltd, with 200 participants enrolled, started 2023-05-26 and due to reach its primary completion in 2025-12. Interventions recorded: MHB036C.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/